Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Single-minded homolog 2 (SIM2)
- Target
- SIM2
- Molecular classification
- Transcription factor, Basic helix–loop–helix (bHLH) PAS protein family
01
Overview
Single-minded homolog 2 (SIM2) is a transcription factor in the basic helix–loop–helix-PAS (bHLH-PAS) family, encoded by the SIM2 gene on chromosome 21q22.2. It is critical for central nervous system midline development, head and face morphogenesis, and plays context-dependent roles in cancer biology. SIM2 acts as a transcriptional regulator by dimerizing with partners such as ARNT/ARNT2, regulating cell cycle, apoptosis, and various metabolic and differentiation pathways. Two main isoforms exist—SIM2-long and SIM2-short (SIM2s). SIM2s is notably a mammary tumor suppressor and represses genes associated with epithelial-mesenchymal transition and cancer progression. Dysregulation of SIM2 is implicated in several cancer types, Down syndrome phenotypes, and potentially neurodevelopmental disorders[1][2][3][4][5][7].
- Other names
- Single-minded homolog 2SIM2BHLHE15bHLHe15MGC119447HMC13F06HMC29C01Class E basic helix-loop-helix protein 15Single-minded family bHLH transcription factor 2Transcription factor SIM2
02
Mechanism of action
Not drug-targeted directly; functions via transcriptional repression/activation through dimerization and DNA binding
03
Biological functions
Regulation of neurogenesis of midline cells in the central nervous systemRegulation of gene expression through dimerization with ARNT or ARNT2Cell cycle regulation (inhibition of cyclin E expression)Tumor suppressor activity, especially in mammary and some epithelial tissuesPromotion of mitochondrial oxidative phosphorylation (OXPHOS) (SIM2s isoform, noncanonical role)Maintenance of genomic stability via interaction with ATM, BRCA1, and RAD51 (homologous recombination repair)
04
Disease associations
Down syndrome (gene located in DS critical region, suggested to contribute to phenotypes)Cancer (roles in colon, breast, prostate cancer; tumor suppressor and oncogenic contexts depending on isoform/tissue)Neurodevelopmental disorders
05
Safety considerations
Not applicable (no direct clinical modulation by drugs; therapeutic manipulation might affect neurodevelopment or genomic stability)
06
Interacting drugs
None known or clinically established as of current knowledge
07
Biomarkers
SIM2s isoform expression as a potential biomarker in breast and colon cancerAltered SIM2 expression linked to tumor progression, especially as downregulated in some cancers or upregulated in colon tumors
Beyond the preview
Go deeper on Single-minded homolog 2 (SIM2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Single-minded homolog 2 (SIM2).